Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study

Summary

This prospective observational study investigated the prognostic value of circulating tumor DNA (ctDNA)-derived tumor fraction (TFx) and copy-number alterations (CNAs) in 78 patients with metastatic castration-resistant prostate cancer (mCRPC) receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 radioligand therapy. Findings revealed that ctDNA-derived TFx serves as a dynamic biomarker for treatment response and progression risk, with a significantly increased risk of progression (HR 4.9) when modeled as a time-dependent variable. Furthermore, a high CNA burden was associated with shorter median overall survival (8.3 vs 13.8 months). The study identified recurrent CNAs affecting key tumor suppressor genes and highlighted the potential of these ctDNA-based biomarkers for clinical stratification and real-time monitoring.

Critical appraisal

Clinical. This prospective observational study (Phase II/III evidence) demonstrates that ctDNA-derived tumor fraction is a dynamic prognostic biomarker for progression risk (HR 4.9) and CNA burden is a prognostic biomarker for overall survival (median OS 8.3 months for high burden vs 13.8 months for low burden) in mCRPC patients treated with PSMA-RLT. These non-invasive biomarkers could be integrated into patient stratification and real-time monitoring strategies, justifying further clinical trials to validate their use in therapeutic decision-making. Clinical impact could be seen in the medium term (3-5 years) to guide treatment intensification or switching.

Molecular biology. The discovery of ctDNA-derived tumor fraction as a dynamic biomarker and CNAs as resistance markers is significant. The use of ultra-low-pass whole-genome sequencing on plasma samples (liquid biopsy) is a non-invasive approach with high analytical validity for detecting these alterations. The identification of recurrent CNAs in key tumor suppressors like PTEN, RB1, BRCA2, and ATM, and their enrichment in TP53 signaling and homologous recombination repair pathways, provides mechanistic insights into treatment resistance. These findings could lead to the development of clinical tests to identify patients at risk of progression or resistance, and potentially to targeted therapies.

Bioinfo & AI. The study utilized established bioinformatics tools such as ichorCNA for tumor fraction estimation and GISTIC2.0 for identifying recurrent CNAs. The unsupervised clustering approach to group patients based on CNA burden, which strongly correlated with tumor fraction, is a relevant data analysis application. The ability to track the persistence and expansion of specific amplifications over time demonstrates the utility of longitudinal analyses. These bioinformatics methods, if integrated into clinical pipelines, could enhance the workflow for variant review and patient prioritization for multidisciplinary tumor board discussions.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology